BUZZ-Aligos rises as mid‑stage trial for hepatitis B drug advances

Reuters01-21

** Shares of biotech firm Aligos Therapeutics ALGS.O up 3% at $8.25

** Co says it is testing its experimental hepatitis B drug, pevifoscorvir sodium, aimed at blocking virus replication, in a mid-stage study with 144 patients

** Expects first interim data from study in early 2026, main results in 2027

** ALGS says earlier tests showed the oral drug reduced infection markers

** Separately, co announced that its chief medical officer, Dr Hardean Achneck, has resigned and a search for a successor is underway

** ALGS was down ~25% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605485995?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-21 23:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605485995","market":"fut","top_or_hot":-1,"title":"BUZZ-Aligos rises as mid‑stage trial for hepatitis B drug advances","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Aligos rises as mid‑stage trial for hepatitis B drug advances</title></head><body><p>** Shares of biotech firm Aligos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>ALGS.O</span> up 3% at $8.25</p><p>** Co says it is testing its experimental hepatitis B drug, pevifoscorvir sodium, aimed at blocking virus replication, in a mid-stage study with 144 patients</p><p>** Expects first interim data from study in early 2026, main results in 2027</p><p>** ALGS says earlier tests showed the oral drug reduced infection markers</p><p>** Separately, co announced that its chief medical officer, Dr Hardean Achneck, has resigned and a search for a successor is underway</p><p>** ALGS was down ~25% in 2025</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Aligos rises as mid‑stage trial for hepatitis B drug advances</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Aligos rises as mid‑stage trial for hepatitis B drug advances\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-21 23:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Aligos rises as mid‑stage trial for hepatitis B drug advances</title></head><body><p>** Shares of biotech firm Aligos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>ALGS.O</span> up 3% at $8.25</p><p>** Co says it is testing its experimental hepatitis B drug, pevifoscorvir sodium, aimed at blocking virus replication, in a mid-stage study with 144 patients</p><p>** Expects first interim data from study in early 2026, main results in 2027</p><p>** ALGS says earlier tests showed the oral drug reduced infection markers</p><p>** Separately, co announced that its chief medical officer, Dr Hardean Achneck, has resigned and a search for a successor is underway</p><p>** ALGS was down ~25% in 2025</p><p>(Reporting by Sahil Pandey in Bengaluru)</p><p>((Sahil.Pandey@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALGS","symbol_name":"Aligos Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nL4N3YM1HP:1","article_id":"2605485995","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605485995","pubTimestamp":1769007631,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Aligos rises as midstage trial for hepatitis B drug advances** Shares of biotech firm Aligos Therapeutics ALGS.O up 3% at $8.25** Co says it is testing its experimental hepatitis B drug, pevifoscorvir sodium, aimed at blocking virus replication, in a mid-stage study with 144 patients** Expects first interim data from study in early 2026, main results in 2027** ALGS says earlier tests showed the oral drug reduced infection markers** Separately, co announced that its chief medical officer, Dr Hardean Achneck, has resigned and a search for a successor is underway** ALGS was down ~25% in 2025","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALGS":"Aligos Therapeutics, Inc.","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"随着乙肝药物中期试验的进展，BUZZ-Aligos股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALGS":0.9},"content_text":"BUZZ-Aligos rises as mid‑stage trial for hepatitis B drug advances** Shares of biotech firm Aligos Therapeutics ALGS.O up 3% at $8.25** Co says it is testing its experimental hepatitis B drug, pevifoscorvir sodium, aimed at blocking virus replication, in a mid-stage study with 144 patients** Expects first interim data from study in early 2026, main results in 2027** ALGS says earlier tests showed the oral drug reduced infection markers** Separately, co announced that its chief medical officer, Dr Hardean Achneck, has resigned and a search for a successor is underway** ALGS was down ~25% in 2025(Reporting by Sahil Pandey in Bengaluru)((Sahil.Pandey@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605485995","isCrawlerRequest":true}